Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $32 to $50.
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $32 to $50.